Tissue adhesion formation control

• US 20050163781A1
• Filed: 01/29/2003
• Published: 07/28/2005
• Est. Priority Date: 01/29/2002
• Status: Abandoned Application

• Current Assignee: KU Leuven Research & Development, Thromb-X, Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw
• Original Assignee: KU Leuven Research & Development, Thromb-X, Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw
• Inventors: Sanabria, Carlos Roger Molinas, Carmeliet, Peter, Collen, Desire, Koninckx, Philippe
• Application Number:
  US10/502,639
• Publication Number:
  US 20050163781A1
• Time in Patent Office: Days
• US Class Current: 424/155.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: C07K 14/4702 Regulators; Modulating activity
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/1136 against growth factors, growth regulators, cytokines, lymphokines or hormones
• CPC Class Codes: C12N 2310/12 catalytic nucleic acids, e.g. ribozymes
• CPC Class Codes: C12N 2310/13 Decoys

Abstract

The present invention is concerned with compositions for use in the medical art. More particularly the invention relates to uses of inhibitors against hypoxia-induced genes for the manufacture of a medicament to prevent and/or to suppress post-operative/post-wounding adhesions formation. Post-operative adhesions are an unwanted result from surgery and are a major source of postoperative morbidity and mortality. The invention applies to human and veterinary applications. To date, no single therapeutic approach has proven universally effective in preventing formation of post-operative adhesions formations.

Claims

1. A method of using a compound that inhibits the expression and/or activity of a hypoxia-induced gene a medicament for treatment of adhesion formation wherein said hypoxia induced gene is selected from the group consisting of a hypoxia inducible factor, a placental growth factor and a vascular endothelial growth factor-B.

2. The method according to claim 1, wherein the compound inhibits the expression and/or activity of placental growth factor.

3. The method according to claim 2, wherein the compound is selected from the group consisting of a nucleotide (antisense, siRNA, RNA aptamer), a small molecule, an antibody, a ribozyme, a transdominant receptor, and a tetrameric peptide.

4. The method according to claim 1, wherein said compound inhibits the expression and/or activity of a hypoxia inducible factor.

5. The method according to claim 4, wherein the compound is selected from the group consisting of a nucleotide (antisense, siRNA, RNA aptamer), a small molecule, an antibody, a ribozyme, geldanamycin derivatives, barbituric acid analogues, inhibitory HIF polypeptides, tumor suppressor protein p14^ARF, and a polypeptide designated as PR-11.

6. The method according to claim 1, wherein said compound inhibits the expression and/or activity of VEGF-B.

7. The method according to claim 6, wherein the compound is selected from the group consisting of a nucleotide (antisense, siRNA, RNA aptamer), a small molecule, an antibody, a ribozyme, a transdominant receptor, and a tetrameric peptide.